Abstract
The streptococcal fibrinolytic principle (streptokinase) has been demonstrated to be an effective agent, in vivo, in patients as a means of mediating the relatively rapid liquefaction of extravascular fibrin coagulums (1). Streptokinase (referred to in this article as SK) has also been shown to be useful as a therapeutic reagent, by which massive extravascular clots may be eradicated by liquefaction and aspiration (2). These findings have received extensive confirmation. (See Footnote 12 to the list of References.) It is the purpose of this article to describe the results of studies of the intravenous administration of SK into patients. The ultimate objective of the study is directed toward attempting to determine whether or not clots occurring within the vascular system as a result of disease may be subject to
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call